Compare Occidental Petroleum Corporation (OXY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs Tango Therapeutics Inc. — how do they compare? Occidental Petroleum Corporation trades at $61.77 (market cap $61.39B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Occidental Petroleum Corporation is far larger — about 16.4× Tango Therapeutics Inc.'s market cap, and Occidental Petroleum Corporation pays a 1.82% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Occidental Petroleum Corporation for 92 Days and Tango Therapeutics Inc. for 0 Days on average.
| OXY | TNGX | |
|---|---|---|
Market Cap | $61.39B | $3.75B |
Volume | 8,708,264 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $66.24 | $32.90 |
52-Week Low | $38.92 | $7.50 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $80.15B | $2.77B |
Dividend Yield | 1.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $61.65, up 0.85% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $70.92. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Financials show strong profitability with a 30.32% net income margin and robust cash flow, though revenue has declined from 2022 peaks. Recent news highlights focus on dividend reliability and Goldman Sachs' upgrade citing cash flow targets and debt reduction.
OXY presents a favorable outlook with earnings momentum, attractive valuation multiples, and analyst support, but faces risks from oil price volatility and competitive pressures. The stock's upside potential hinges on execution of debt reduction and sustained operational efficiency amid energy market fluctuations.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
